Scribe Therapeutics IPO: What Investors Need to Know
Scribe Therapeutics, Inc. (NASDAQ: SCTX) is expected to list on 2026-07-24 at a price range of $13.00 to $15.00 per share. The company is offering 7,150,000 shares, with a disclosed market cap of $123,337,500. The bull case is a differentiated CRISPR platform aimed at cardiometabolic disease; the bear case is an early-stage story with no approved products and substantial going-concern risk.
Scribe Therapeutics, Inc. (NASDAQ: SCTX) is expected to list on 2026-07-24 at a price range of $13.00 to $15.00 per share. The company is offering 7,150,000 shares, with a disclosed market cap of $123,337,500. The bull case is a differentiated CRISPR platform aimed at cardiometabolic disease; the bear case is an early-stage story with no approved products and substantial going-concern risk.
Quick Facts
Expected listing date: July 24, 2026
Exchange: NASDAQ
Proposed symbol: SCTX
Price range: 13.00 - 15.00
Shares offered: 7.15M shares
Implied market cap: $123M
Status: Expected
Company Overview
Scribe Therapeutics is a genetic medicines company building CRISPR-based therapeutics for in vivo use, with a current focus on cardiometabolic disease. Its lead programs are STX-1150 for LDL-C lowering, STX-1200 for elevated Lp(a), and STX-1400 for triglycerides. The company also says it is developing enabling technologies called ELXR and XE as part of its “CRISPR by Design” approach.
The business is still in the development stage. Scribe says it was founded in 2017 and is based in Alameda, California, where it leases 28,304 square feet of office and lab space through November 2029. The company’s strategy is to engineer CRISPR systems that improve activity, specificity, and delivery, which is the core challenge in moving gene editing from the lab into durable human therapies.
Scribe is operating in a crowded but still early CRISPR market that includes companies pursuing gene editing, base editing, and prime editing approaches. The broader opportunity is tied to durable, one-time treatments for large chronic diseases, especially in cardiometabolic care, where LDL-C, Lp(a), and triglycerides represent major commercial targets. That said, the category remains clinically and regulatorily unproven for many indications, so execution matters more than the long-term narrative.
Why They're Going Public
The filing says IPO proceeds will be used to advance STX-1150, STX-1200, and STX-1400 through development, continue investment in other pipeline programs and CRISPR technologies such as ELXR and XE, fund working capital and general corporate purposes, and potentially in-license, acquire, or invest in complementary technologies, assets, manufacturing capabilities, or intellectual property.
For Scribe, the public listing is mainly a financing event that extends runway and supports the next phase of preclinical and development work. It also gives the company a currency for future partnerships or strategic transactions, which matters in a field where platform companies often need collaboration capital before any product reaches the market.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Scribe has no product revenue. All revenue to date has come from collaboration and license arrangements with strategic partners. Collaboration revenue was $27.4 million in 2024 and $51.2 million in 2025, an 87% increase year over year. For the three months ended March 31, 2026, collaboration revenue was $2.2 million, down from $17.1 million in the same period of 2025.
Profitability remains far away. The company reported a net loss of $47.8 million in 2024 and $21.8 million in 2025. For the first quarter of 2026, net loss widened to $17.4 million from $3.4 million a year earlier. The filing does not disclose gross margin, and because the company is pre-commercial, there is no product margin profile to evaluate yet. The company also disclosed substantial doubt about its ability to continue as a going concern, which is the clearest signal that new capital is not optional.
Risk Factors
The biggest risk is that Scribe is still an early-stage platform with no clinical trials completed and no approved products. The company itself says genetic medicine and epigenetic modification are novel and unproven for human therapeutic use, and it warns that preclinical results may not translate into clinical success. That makes the path from scientific promise to commercial product long and uncertain.
Financial and dilution risk are also front and center. Scribe has a history of operating losses, no product revenue, and substantial doubt about its ability to continue as a going concern. It will need additional capital, and the IPO is only one part of that equation. Investors should also watch the 180-day lockup, because the company had 50,511,767 shares outstanding on a fully converted basis as of July 10, 2026, while the offering itself is relatively small versus the fully diluted share count.
Competition is another major issue. Scribe is entering a field with established public names and well-funded private rivals pursuing CRISPR, base editing, and prime editing. Even if the science works, the company still has to prove it can deliver a differentiated therapeutic profile in cardiometabolic disease, where safety, durability, and delivery will be scrutinized closely by regulators and partners.
Comparable Public Companies
The closest public comps are CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Beam Therapeutics (BEAM), Editas Medicine (EDIT), and Prime Medicine (PRME). All are part of the broader gene-editing group, but Scribe is earlier than most of them because it has not yet completed clinical trials and has no approved products. That makes Scribe more of a platform-stage story than a commercial biotech.
Relative to these peers, Scribe’s IPO looks modest in size at 7.15 million shares and a $13 to $15 range, implying a midpoint raise of about $96.2 million before overallotment. The company’s disclosed market cap of $123,337,500 also suggests a smaller starting valuation than many established public gene-editing names, which may appeal to investors looking for earlier-stage exposure but also means the stock will likely trade on pipeline updates rather than near-term revenue.
The sector backdrop is mixed rather than euphoric. Gene-editing stocks have tended to move sharply on clinical data, partnership news, and financing conditions, and the group is still highly sensitive to risk appetite. The market is open to differentiated genetic medicine stories, but it is not rewarding unproven platforms indiscriminately, so Scribe will be priced against both the promise of cardiometabolic gene editing and the reality of a long development timeline.
Verdict
What to watch as Scribe prices is whether investors are willing to underwrite an early CRISPR platform with no clinical data yet but a clear disease focus in cardiometabolic medicine. The setup favors a story-driven IPO rather than a fundamentals-driven one: the company has collaboration revenue, strategic backers, and a defined pipeline, but it also carries going-concern language and a long path to commercialization. That combination usually means valuation discipline matters more than headline science.
The timing angle is straightforward: this is a gene-editing IPO trying to tap a market that still likes durable-therapy narratives, but only when the story is specific and the capital structure is reasonable. Scribe’s emphasis on LDL-C, Lp(a), and triglycerides gives it a recognizable commercial angle, which helps, yet the real test will be whether the offering clears at a level that leaves room for execution risk. Shareholders should watch the final pricing, the implied float, and whether the market treats this as a credible cardiometabolic platform or just another early biotech needing more proof.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
